PARAGON HEALTHCARE

A Carelon Company

OMVOH (MIRIKIZUMAB) ORDER SET

P: 877-365-5566 | **F:** 855-889-2946

PATIENT INFORMATION

Fax completed form, insurance information, and clinical documentation to 855-889-2946

Name:		DOB:		Gender: ☐ Female ☐ Male	
Address:		City:	State:		ZIP:
Phone:	Email:	Height:	☐ inches ☐ cm	Weight:	☐ lbs. ☐ kg
Allergies:					
Diagnosis Code ICD-10 (required):		**Diagnosis Description:**			
Patient Status: ☐ New to Therapy ☐ Continuing Therapy		Next Treatment Date:			

PHYSICIAN INFORMATION

Prescriber Name:		Phone:	Fax:
Office Contact:			Email:
Address:		City: State:	ZIP:
NPI #:	DEA#:		Tax ID:

INSURANCE INFORMATION (or attach copy of cards)

Primary Insurance:	Policy #:	Group #:
Secondary Insurance:	Policy #:	Group #:

PRESCRIPTION INFORMATION (or attach a copy of the prescription)

Drug	Dosing	Refills
Omvoh IV (mirikizumab)	☐ 300mg IV at week 0, 4, and 8 ☐ 900mg IV at week 0, 4, and 8 ☐ Other: _____	None
Omvoh SubQ (mirikizumab)	SubQ doses to be evaluated by Paragon Specialty Pharmacy ☐ 200mg subcutaneously at week 12, then every 4 weeks thereafter ☐ 300mg subcutaneously at week 12, then every 4 weeks thereafter ☐ Other: _____	☐ x 1 year ☐ _____

Other orders: _____

Lab Orders: _____ Lab frequency**:** ☐ Prior to 4 and 8 week dose ☐ Other: _____

LFTs and Bilirubin should be monitored at baseline, during first 24 weeks of treatment, and periodically

Required labs to be drawn by: ☐ Paragon ☐ Referring Provider

As required by your state, Prescriber to check "Dispense as written" or handwrite "Brand Medically Necessary" and sign to prevent generic substitution. ☐ Dispense as written

PRESCRIBER SIGNATURE

By signing this form and utilizing our services, you are authorizing *Paragon Healthcare, Inc.* and its employees to serve as your prior authorization and specialty pharmacy designated agent in dealing with medical and prescription insurance companies, and to select the preferred site of care for the patient.

Prescriber Signature: X **Date:**

PARAGON HEALTHCARE

A Carelon Company

COMPREHENSIVE SUPPORT FOR OMVOH (MIRIKIZUMAB) THERAPY

PATIENT INFORMATION

Name: DOB:

REQUIRED DOCUMENTATION FOR REFERRAL PROCESSING & INSURANCE APPROVAL

☐ Include signed and completed order (MD/prescriber to complete page 1)

☐ Include patient demographic information and insurance information

☐ Include patient's medication list

☐ Supporting clinical notes to include any past tried and/or failed therapies, intolerance, benefits, or contraindications to conventional therapy

- ☐ Does the patient have a contraindication/intolerance or failed trial to corticosterioids or immunomodulators (i.e., 6-MP, azathioprine, budesonide)? ☐ Yes ☐ No
  If yes, which drug(s)? _____
- ☐ Does the patient have a contraindication/intolerance or failed trial to any biologic (i.e., Humira, Remicade, Stelara, Cimzia)? ☐ Yes ☐ No
  If yes, which drug(s)? _____

☐ Include labs and/or test results to support diagnosis

☐ *If applicable* - Last known biological therapy: _____ and last date received: _____. If patient is switching biologic therapies, please perform a wash-out period of _____ weeks prior to starting Omvoh.

☐ Other medical necessity: _____

REQUIRED PRE-SCREENING

☐ **TB screening test completed - attach results**

- ☐ **Positive** ☐ **Negative**

☐ **Baseline liver function tests and bilirubin - attach results**

If TB results are positive - please provide documentation of treatment or medical clearance, and a negative CXR